Skip to content

Grand Challenges offer opportunities for HIV research funding

Fos-amprenavir gets marketing approval in US, but once daily dose not recommended for PI-experienced

Gilead issues tenofovir/ddI/3TC warning for European doctors - follows US warning last week

New form of liposuction able to reduce buffalo hump - at least in the short term

One in four UK HIV diagnoses are missed says BHIVA

Australian therapeutic vaccine shows promise in treatment interruption

HAART continues to improve survival, but not all HIV risk groups benefit equally

Global Fund approves $359 million for AIDS

GSK gives pan-Africa license to South African firm